Observational studyBMC pulmonary medicine2026
Quantitative CT assessment of structural and functional response to omalizumab in severe allergic asthma: a prospective real-world study.
Observational study in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundWhile omalizumab has demonstrated clinical efficacy in severe allergic asthma, its impact on small airway function and structural changes remains underexplored. We aimed to evaluate the multidimensional effects of omalizumab using physiological, symptomatic, and quantitative CT (QCT) measures.
methodsThis prospective observational study included 25 patients with severe allergic asthma treated with omalizumab for 16 weeks. Assessments included blood eosinophils, fractional exhaled nitric oxide (FeNO), spirometry, body plethysmography, Asthma Control Test (ACT), modified Medical Research Council (mMRC) dyspnea scale, 6-minute walk test (6MWT), inspiratory and expiratory quantitative computed tomography (QCT) scans. Changes before and after treatment were analyzed using paired Student’s t-tests, and Pearson’s correlation was used to explore inter-domain relationships.
resultsAfter 16 weeks of omalizumab treatment, patients showed significant reductions in airway inflammation, with Eosinophil counts showing a downward trend. FeNO decreasing from 69.3 ± 33.3 to 44.8 ± 23.8 ppb (p < 0.001). Maximal expiratory flow at 50% of forced vital capacity (MEF₅₀) increased from 1.89 ± 1.31 to 2.20 ± 1.19 L/s (p = 0.001), and maximal expiratory flow at 25% of forced vital capacity (MEF₂₅) increased from 0.61 ± 0.41 to 0.75 ± 0.52 L/s (p = 0.002). The residual volume/total lung capacity (RV/TLC) ratio decreased from 48.7 ± 10.2% to 41.7 ± 9.3% (p < 0.001). Asthma Control Test (ACT) scores improved from 17.4 ± 0.8 to 20.3 ± 1.2 (p < 0.001). Physical capacity increased, with 6MWT from 296.3 ± 54.5 to 327.9 ± 54.1 m (p < 0.001). QCT revealed a significant reduction in expiratory gas trapping volume from 382.4 ± 248.7 to 285.4 ± 176.1 mL (p = 0.004).
conclusionOmalizumab was associated with short-term (16-week) improvements in type 2 inflammatory markers, pulmonary function, symptom control, and QCT-derived structural measures in patients with severe allergic asthma. QCT imaging showed reduced gas trapping over 16 weeks, suggesting that quantitative imaging may complement symptom-based assessment of biologic response. However, larger studies with longer follow-up are also needed to confirm the durability of these changes and their long-term clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.